JMD Properties, Inc. Acquires Stella Diagnostics
September 2, 2020
JMD Properties, Inc. announced the acquisition of Stella Diagnostics, LLC via a preferred stock transaction and will change its corporate name to Stella Diagnostics, Inc. The deal positions the public company to pivot into the molecular diagnostics / biotech sector to commercialize Stella’s oncology-focused assays for esophageal disease.
- Buyers
- JMD Properties, Inc.
- Targets
- Stella Diagnostics, LLC
- Industry
- Biotechnology
- Location
- Utah, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
-
LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs
October 25, 2024
Healthcare Services
LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.
-
Quest Diagnostics Acquires Haystack Oncology
April 27, 2023
Healthcare Services
Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.
-
P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)
February 11, 2020
Healthcare Services
P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.
-
Becton Dickinson Acquires NAT Diagnostics
May 15, 2020
Medical Devices
Becton Dickinson (BD) has acquired NAT Diagnostics, a molecular diagnostics firm that developed an isothermal NAT Dx technology for rapid point-of-care testing. BD plans to further develop the NAT Dx platform to offer decentralized molecular testing options targeted for early 2023, expanding BD’s capabilities in point-of-care molecular diagnostics.
-
bioMérieux Acquires Specific Diagnostics
April 12, 2022
Medical Devices
bioMérieux has agreed to acquire Specific Diagnostics, a U.S.-based developer of the SPECIFIC REVEAL Rapid AST system, to strengthen its sepsis and antimicrobial stewardship portfolio. bioMérieux will acquire 100% of Specific Diagnostics for a consideration equivalent to 3.3% of bioMérieux's market capitalization as of April 11, 2022, paid in cash and newly issued shares; the deal was expected to close by the end of Q2 2022 subject to regulatory approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.